Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Fluorouracil 7Oxaliplatin 6Nivolumab 5Leucovorin 5fludarabine 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Capecitabine 4zimberelimab 3pembrolizumab 3aldesleukin 3Trastuzumab 3Ramucirumab 3ulixertinib 2trastuzumab deruxtecan 2fludarabine phosphate 2Specimen Handling 2Irinotecan 2Cisplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1toripalimab 1tislelizumab 1sodium propionate 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × KP 1339 × 30 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡